Replimune REPL 深 沪
等待开盘 08-17 09:30:00 美东时间
14.97
-0.220
-1.45%
华盛通- 最 高15.39
- 今 开15.19
- 成交量 239.89万股
- 最 低 14.685
- 昨 收 15.19
- 总市值 12.58亿
- 52周最高 15.705
- 市盈率 静 --
- 换手率 2.85%
- 52周最低 1.50
- 委 比 91.44%
- 总股本 8402.61万
- 历史最高 54.79
- 量 比 0.35
- 振 幅 4.64%
- 历史最低 1.50
- 每 手 1
- 风险率 2.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多财报速睇 | Replimune 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.70亿美元，同比亏损缩窄19.5%
华盛资讯8月15日讯，Replimune公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.70亿美元，同比亏损缩窄19.5%。
08-15 05:22
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
08-15 04:55
财报速睇 | Replimune 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损0.70亿美元，同比亏损缩窄19.5%
华盛资讯8月14日讯，Replimune公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损0.70亿美元，同比亏损缩窄19.5%。
08-14 20:32
Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from the same period last year.
08-14 20:06
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma reported financial results for Q2 2026 and provided updates on its pipeline. The FDA accepted the BLA for obexelimab to treat IgG4-RD with a PDUFA date of May 27, 2027. New bioequivalence data for obexelimab's delivery methods were confirmed. Phase 2 SunStone SLE trial results are expected in Q4 2026. ZB021's Phase 1 trial is ongoing, with initial data anticipated by year-end. Four abstracts for orelabrutinib were accepted for MST...
08-13 11:00
Replimune Raises $150 Million in Equity Offering
Replimune Group ( ($REPL) ) has shared an update. On August 9, 2026, Replimune ...
08-10 20:26
Replimune Prices ~$150M Underwritten Offering Of 9,701,490 Shares And Warrants At $12.06 Per Unit
The aggregate gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering are to be sold by Replimune. The offering is expected to close on August 11, 2026, ...
08-10 20:10
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19
Wedbush analyst Robert Driscoll upgrades Replimune Group (NASDAQ:REPL) from Neutral to Outperform and raises the price target from $12 to $19.
08-07 21:48
Two Rejections, Messy Process: Replimune Finally Secures FDA Approval for Skin Cancer Treatment
The U.S. Food and Drug Administration (FDA) on Thursday granted accelerated approval to Replimune Group Inc. (NASDAQ:REPL) for its Tudriqev (vusolimogene oderparepvec-wtpg), a novel oncolytic immunotherapy. The commercial-stage biotechnology company can now offer this treatment, previously known as ...
08-07 19:49
